CA-MOVEWORKS
22.2.2024 21:01:33 CET | Business Wire | Press release
Moveworks, the leading AI copilot platform for the enterprise, today announced registration for its annual Moveworks.global conference is now open. The event will take place on April 23, 2024, and will be held both virtually and in-person in San Jose, CA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240222535446/en/
In an era where artificial intelligence is not just an advantage but a necessity, Moveworks.global is the must-attend event for industry leaders, developers, and forward-thinkers eager to explore the transformative power of generative AI in business. This event serves as a dynamic platform for participants to engage with the brightest minds in the industry.
With past speakers from world-renowned companies like OpenAI, Salesforce, Honeywell, and more, attendees will learn firsthand how best-in-class organizations are leveraging generative AI to foster unprecedented levels of business agility. From global corporations to smaller enterprises eager to harness the potential of generative AI, Moveworks.global promises to offer invaluable insights for leveraging AI to gain a competitive edge.
Event highlights include:
- Unlocking productivity: Discover the untapped potential of centralizing search and action to streamline operations while enhancing productivity.
- AI adaptability through reasoning: Learn why advanced AI reasoning capabilities are crucial for creating adaptable, intelligent systems that can meet evolving business needs.
- Custom AI solutions: Gain practical knowledge on customizing AI tools to align with specific business processes — accelerating growth and innovation.
- Continuous improvement: Hear success stories and proven strategies from various industries on driving continuous service improvement through AI.
Whether you're aiming to integrate AI into your organization or develop AI-driven solutions, Moveworks.global will open new horizons and inspire actionable strategies for leveraging generative AI within the enterprise.
“Moveworks.global is more than just a conference — it's a catalyst for transformative change with AI,” said Bhavin Shah, CEO and founder of Moveworks. “This year, we're zeroing in on tangible generative AI successes, showcasing actual outcomes and practical frameworks from industry pioneers. It's a unique opportunity to learn from those who've turned their AI visions into reality.”
Join us at Moveworks.global to be at the forefront of the AI revolution in business. Register today to secure your place among leaders pioneering the future of enterprise AI.
For more information and to register, visit: https://global.moveworks.com/2024.
About Moveworks
Moveworks is the leading AI copilot platform for the enterprise. It empowers the workforce to interact with and take action across all business systems through natural language. Powered by the world’s most advanced LLMs and our proprietary MoveLM model, the Moveworks copilot enables users to search information, take action, automate tasks, and generate factually accurate content with generative AI. Companies such as Databricks, Broadcom, Hearst, and Toyota North America leverage Moveworks' out-of-the-box solutions and intuitive developer tools to automate L1 support, enhance the employee experience, and accelerate business transformation.
Founded in 2016, Moveworks has raised $315 million in funding, at a valuation of $2.1 billion. In 2023, it was named to the Forbes Cloud 100 list — a definitive list of the top private cloud companies in the world — and has been included in Forbes’ AI 50 list for five consecutive years.
For more information, visit: Moveworks.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222535446/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom